Serum platelet-activating factor acetylhydrolase activity: a novel potential inflammatory marker in type 1 diabetes

Prostaglandins & Other Lipid Mediators
Marilia de Brito GomesEduardo Tibiriçá

Abstract

Plasma activity of the platelet-activating factor acetylhydrolase (PAF-AH) plays an important role in inflammation and atherosclerotic process in chronic diseases. We aimed to evaluate the levels of PAF-AH activity and their association with the metabolic profile and chronic complications in patients with type 1 diabetes. The study included 118 outpatients (54 males) aged 27.1+/-11.3 years with disease duration of 12.3+/-8.5 years with (n=38) or without (n=80) diabetes complications and 96 control subjects (48 males) matched for age, gender, body mass index and smoking habits. The serum levels of PAF-AH activity were higher in patients either with or without chronic complications (16+/-5.3 and 14+/-5.4 nmol/(min mL), respectively) than in controls (13+/-5.1 nmol/(min mL), P=0.02). In the total population, PAF-AH activity was correlated with age, HDL-cholesterol, total cholesterol and LDL-cholesterol. In patients, PAF-AH activity was correlated with age, HbA1c, uric acid, HDL-cholesterol, cholesterol, LDL-cholesterol, cholesterol/HDL-cholesterol ratio and the LDL-cholesterol/HDL-cholesterol ratio. It is concluded that PAF-AH plasma activity could be a novel candidate for low-grade inflammatory marker in patients with type 1 diab...Continue Reading

References

Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Nov 26, 1999·Biochimica Et Biophysica Acta·Z S Derewenda, Y S Ho
Jun 22, 2000·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·P Cavallo-PerinG Camussi
Nov 18, 2000·Biochimica Et Biophysica Acta·L W Tjoelker, D M Stafforini
May 26, 2001·Diabetes Care·T J OrchardUNKNOWN Pittsburgh Epidemiology of Diabetes Complications Study
Apr 9, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Adriana R SilvaHugo C Castro-Faria-Neto
Sep 28, 2002·Diabetes Care·Helen M ColhounCoen D A Stehouwer
Jan 18, 2003·Biochimica Et Biophysica Acta·Makoto Mark Taketo, Masahiro Sonoshita
Jan 28, 2003·Progress in Lipid Research·Ken KarasawaMorio Setaka
Oct 4, 2003·Diabetes & Metabolism·M B GomesH J Matos
Dec 6, 2003·Hypertension·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Dec 25, 2003·Diabetes Care·Mark E MolitchUNKNOWN American Diabetes Association
Sep 15, 2004·Diabetes Research and Clinical Practice·Marília B Gomes, Verônica G Nogueira
Jan 25, 2005·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Evangelos RizosMoses Elisaf
Jan 20, 2006·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Eleni C PapavasiliouAlexandros D Tselepis
Sep 26, 2007·Expert Review of Molecular Diagnostics·John F CarlquistJeffrey L Anderson

❮ Previous
Next ❯

Citations

Nov 15, 2011·Prostaglandins & Other Lipid Mediators·Paraskevi DetopoulouSmaragdi Antonopoulou
Jul 25, 2019·Diabetic Medicine : a Journal of the British Diabetic Association·J SeyfarthJ Rosenbauer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Related Papers

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
P Cavallo-PerinG Camussi
Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]
Katherine M HowardNipa Patel
© 2022 Meta ULC. All rights reserved